Keywordsmitochondrial nutrients; mitochondrial dysfunction; oxidative stress; oxidative phosphorylation; Krebs cycle; autophagy; modulators; erythropoiesis; cardiac ischemia/reperfusion injury; low T3 syndrome; mitochondrial dysfunction; cardioprotection; androgen receptor; granulosa cell; PGC1-β; mitochondria; mitochondria; aging; skeletal muscle; proton leak; mitochondrial DNA; DNA replication; DNA repair; RECQ4; Twinkle; PIF1; DNA2; SUV3; platelets; mitochondria; reactive oxygen species; doxorubicin; apoptosis; aging; mitochondrial oxidative stress; mitochondrial DNA damage; vascular dysfunction; autophagy; mevalonate pathway; mitochondrial dysfunction; inflammation; Mevalonate Kinase Deficiency; statins; thyroid hormone; mitochondria; uncoupling mechanisms; mitochondrial biogenesis; metabolism; energy expenditure; thyroid hormone receptors; mitochondria; cancer; drug delivery systems; photodynamic therapy; combination therapy; septic cardiomyopathy; mitochondrial dysfunction; heart; bioenergetics; mtDNA maintenance; multiple mtDNA deletions; adult mitochondrial disorders; progressive external ophthalmoplegia; mitochondrial myopathy; mitochondria; unfolded protein response; cell signaling; gene expression; ageing; mitochondria; ubiquitin; proteasome; ROS; mtTFA; mtDNA; cisplatin; cancer chemotherapy; prognosis; Parkinson’s disease; mitochondrial dysfunction; mitochondrial dynamics; mitochondrial DNA damage; oxidative stress; Sirtuin 3; alveolar epithelial cell; pulmonary fibrosis; mitochondria; OPA1; Oma1; Yme1L; oxygen-glucose deprivation (OGD); hypoxia-ischaemia; neonatal brain injury; low T3 state; ischemia/reperfusion; mitochondrial function; mitochondria proteomic profiling; cancer therapy; solid tumor; mitochondria; oxidative phosphorylation; glucose; multicellular tumor spheroids; n/a
